Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. by Parkes, G, Greenhalgh, T, Griffin, M, Dent, R

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia by Preiss, D, Rosenson, R, Jacobsen, T, Djedjos, C, Dent, R, Bridges, I, Miller, M

Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies by Sattar, N, Valensi, P, Preiss, D, Dent, R, Bridges, I, Ruzza, A, Cyrille, M, Handelsman, Y

Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies by Toth, P, Descamps, O, Genest, J, Sattar, N, Preiss, D, Dent, R, Djedjos, C, Wu, Y, Geller, M, Uhart, M, Somaratne, R, Wasserman, S, for the PROFICIO Investigators